Eyes on China: The Race to Lead a USD 9.5 Billion Ophthalmology Market
With nearly half of Chinese adults now suffering from myopia and age-related eye conditions on the rise, China is on the brink of an ophthalmology boom — a market set…
Address: Institute of Medicinal Plant Development
151 Ma Lian Wa North Road, Haidian District
Beijing, P.R.China, 100193,China
Tel: +86 10 62899958
Web: www.abo.org.cn
ALLIANCE OF BIO-BOX OUTSOURCING, CHINA (ABO) is a member-based organization, devoted to excellence in providing high quality, efficient and cost-effective services and promoting international collaborations between China and the world.
ABO was founded in 2005 by the Beijing Pharma and Biotech Center (BPBC), together with 10 leading biotech outsourcing providers in China.
ABO provides a broad range of services, from drug discovery, pre-clinical studies, clinical trials, to registration and contract manufacturing. Alliance of Bio-Box Outsourcing China offers hassle-free outsourcing experiences with global quality standards.
Genomics Studies & Proteomics Studies, Genetic Engineering & Protein Engineering, Genetic Therapeutics, Antibody Engineering, Drug Screening Pharmacokinetics & Drug Safety Evaluation, Pilot Plan Trials, Clinical Trials, Contract Manufacturing
With nearly half of Chinese adults now suffering from myopia and age-related eye conditions on the rise, China is on the brink of an ophthalmology boom — a market set…
A summary of top stories from China’s pharma industry: Sciwind Biosciences presents promising trial data for its obesity contender; Simcere reaches approval for its Idorsia-partnered insomnia therapy; AstraZeneca inks AI-enabled…
Swapping the predictability of venture capital for the high-stakes volatility of biotech entrepreneurship, John Zhu set out to build something few in China had dared: a globally oriented biopharma with…
Ye Liu, CEO and cofounder of OcuMension Therapeutics, speaks about the challenges and triumphs of running one of China’s most ambitious ophthalmology-focused biopharmaceutical companies. Launched with USD 5 million and…
Building a biotech from the ground up is rarely the next step for someone who has led multinational pharmaceutical giants. Yet that was the challenge Pony Lu accepted when he…
2024 marks a moment of inflection for Harbour BioMed, as the company collect the rewards of a strong global execution. In this interview, Dr Jingsong Wang reflects on the strategic,…
As a result of its ageing demographic, China has seen a sharp rise in Alzheimer’s Disease (AD). The country’s AD patients over 60 already total some ten million and as…
This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers China’s USD 36.2bn in outbound licensing agreements, Henlius & EssexBio meeting Phase III endpoints, Organon acquiring US…
This week’s Asia healthcare and pharma roundup from PharmaBoardroom content partner Selesta covers the AACR 2025 ADC pipeline list from China, Puhe out-licensing global rights of a PRMT5 inhibitor to…
2024 was another groundbreaking year for Chinese medicine approvals. Writing in the March 2025 edition of DIA’s Global Forum magazine, Juan Valencia S. and Angel Shao of PharmCube explain how…
Illumina has been swept into the trade conflict between the US and China. After the Trump administration declared a 10 percent tariff on Chinese goods in February, Beijing retaliated by…
A roundup of some of the biggest stories coming out of China’s pharma industry, including the news that AstraZeneca may be seeing the other side of country’s probes; the counter-sanction…
See our Cookie Privacy Policy Here
